Blood Cancer

How a Cure for Hodgkin Lymphoma Changed the Course of Cancer Treatment

by

To mark its 50th anniversary, the American Society of Clinical Oncology (ASCO) invited physicians, patients, and the public to name the most important advances in clinical cancer research in the past half century. From more than 2,000 responses, the top choice was a cure for advanced Hodgkin lymphoma developed by scientists at the National Cancer … Read more

Remembering My Father’s Journey with Multiple Myeloma

by

By Elise Renner There’s a 1-in-12 chance that this is the month yours or your loved one’s cancer is recognized—odds better than the survival rates for some of these diseases. Some months, like October, boast big names like breast cancer. Others, like September, are crowded with lesser-known branches of the disease. “Cancer apparel,” including ribbons … Read more

What Is Waldenström’s Macroglobulinemia?

by

Waldenström’s macroglobulinemia (Waldenström’s) is a slow-growing type of non-Hodgkin lymphoma marked by abnormal levels of an antibody called macroglobulin (IgM). Also known as lymphoplasmacytic lymphoma, Waldenström’s mostly forms in the bone marrow and can hinder the growth of normal blood cells, which can lead to anemia as well as a weakened immune system. Waldenström’s sometimes … Read more

New Treatment Option for Patients with Rare Blood Cancer

by

It’s commonly thought that targeted therapy for cancer requires the development of separate drugs for each type and subtype of cancer. The recent approval of the drug ibrutinib (Imbruvica®), however, for Waldenström’s macroglobulinemia (a rare form of lymphoma) shows the opposite to be true: a single agent can be effective against multiple types of cancers, providing … Read more

New, Faster Test Speeds Up Treatment for Blood Cancers

by

Rapid Heme Panel, a new quick-turnaround genetic diagnostic test, at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), offers some patients with aggressive blood cancers faster diagnoses, and treatments. Instead of sending blood samples to different laboratories for tests that return results in two weeks or more, Rapid Heme Panel puts the results in doctors’ hands in … Read more

The Latest Research and Treatment for Blood Cancers and Disorders

by

In the treatment of blood cancers and disorders, doctors and researchers are focusing their sights on the immune system and how to bolster its ability to fight off diseases like leukemia, lymphoma and multiple myeloma. “Understanding how you control the immune system is a big theme in treatment for these diseases,” says David A. Williams, … Read more

Research Advances Hold Promise for Multiple Myeloma Treatment

by

Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. … Read more

A History of Multiple Myeloma Advances

by

Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many patients a chronic, and more manageable disease, with prognosis now improved to median survivals of seven to ten years.

Here is a look at how DF/BWCC physician-scientists and patients have helped lead the way toward improved treatment for multiple myeloma over the past three decades.

Read more

Hodgkin Lymphoma: Five Things You Need to Know

by

Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the Reed-Sternberg cell.

Arnold Freedman, MD, clinical director of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answers some questions about the disease:

Read more

Clinical Trials and the Future of Lymphoma Treatment

by

Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.

“Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.

Read more

Marine Conquers Leukemia with Support from Family and the Massachusetts State Police

by

This Veteran’s Day, Dana-Farber thanks our patients, survivors, families, and friends who have served or are serving in the armed forces, including survivors Stacey Carroll, Ben Groen, and Tim Crowley, who tells his story below.

In June 2010, I was diagnosed with acute myeloid leukemia (AML), a fast-moving disease where too many immature white blood cells are present in the blood and bone marrow, after doctors found abnormalities in routine blood work for the Marines. My wife, Julie, and I were in shock. We had just celebrated Father’s Day with our two young children, Jack and Kate, and now we would be spending the foreseeable future at Dana-Farber/Brigham and Women’s Cancer Center.

Read more

An Overview of Lymphoma Therapy

by

More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas.

Two decades after the war, a thoracic surgeon named Gustav Lindskog used nitrogen mustard to successfully treat a patient with non-Hodgkin’s lymphoma.

Read more